Guizhou Sanli Pharmaceutical Co Ltd Class A 603439
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- CNY 13.79
- Day Range
- CNY 13.50–13.85
- 52-Week Range
- CNY 11.92–20.34
- Bid/Ask
- CNY 13.72 / CNY 13.73
- Market Cap
- CNY 5.62 Bil
- Volume/Avg
- 4.4 Mil / 5.2 Mil
Key Statistics
- Price/Earnings (Normalized)
- 22.34
- Price/Sales
- 3.27
- Dividend Yield (Trailing)
- 0.73%
- Dividend Yield (Forward)
- 1.46%
- Total Yield
- 0.73%
Company Profile
Guizhou Sanli Pharmaceutical Co Ltd is engaged in Chinese pharmaceutical research, development, production and marketing. The company produces and sells soft capsules, hard capsules, sprays (including Chinese medicine extraction) and provides Chinese medicine science and technology consulting services. Its products include Pediatric medication; Respiratory system medication; Cardiovascular and cerebrovascular drugs; Digestive medicine; Trauma injury medication; Rehabilitation medicine; and Ophthalmic medicine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,557
- Website
- http://www.gz-sanli.com
Comparables
Valuation
|
Metric
|
603439
|
600594
|
600079
|
|---|---|---|---|
Price/Earnings (Normalized) | 22.34 | — | 16.13 |
Price/Book Value | 3.65 | 0.88 | 1.74 |
Price/Sales | 3.27 | 0.91 | 1.23 |
Price/Cash Flow | 19.64 | 5.98 | 13.20 |
Price/Earnings
603439
600594
600079
Financial Strength
|
Metric
|
603439
|
600594
|
600079
|
|---|---|---|---|
Quick Ratio | 1.65 | 1.25 | 1.13 |
Current Ratio | 1.96 | 1.90 | 1.48 |
Interest Coverage | 44.37 | 1.12 | 10.09 |
Quick Ratio
603439
600594
600079
Profitability
|
Metric
|
603439
|
600594
|
600079
|
|---|---|---|---|
Return on Assets (Normalized) | 12.93% | −0.73% | 4.88% |
Return on Equity (Normalized) | 21.60% | −1.16% | 10.68% |
Return on Invested Capital (Normalized) | 16.14% | −0.40% | 6.91% |
Return on Assets
603439
600594
600079
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Lpgcqnrhz | Qnnlnm | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bvgysgnn | Vdbrz | $114.2 Bil | |||
| Moderna Inc
MRNA
| Yxvzczss | Tqhx | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Lbvytrs | Hhr | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Bdfnbkv | Wtcf | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Yfnpshvwc | Gmylft | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Sdlwcmxsf | Mrwpg | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Gkpgkpshb | Tlcc | $12.8 Bil | |||
| Incyte Corp
INCY
| Qcxsyrf | Tjkdv | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Hpwjvqxmrw | Ngvbhpx | $12.2 Bil |